Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.
about
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetesCommon medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?Origin and therapy for hypertriglyceridaemia in type 2 diabetesIncretin based therapies: a novel treatment approach for non-alcoholic fatty liver diseaseGLP-1-based strategies: a physiological analysis of differential mode of actionDipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protectionDifferential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort studyGlucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.Linagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function.Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans.The regulatory role of DPP4 in atherosclerotic disease.Effect of sitagliptin on lipid profile in patients with type 2 diabetes mellitus.Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular systemStudy of postprandial lipaemia in type 2 diabetes mellitus: exenatide versus liraglutide.Cardiovascular effects of incretin therapy in diabetes care.Single administration of vildagliptin attenuates postprandial hypertriglyceridemia and endothelial dysfunction in normoglycemic individuals.Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetesElectroacupuncture-induced cholinergic nerve activation enhances the hypoglycemic effect of exogenous insulin in a rat model of streptozotocin-induced diabetesLipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitorsPractical Application of Antidiabetic Efficacy of Lycium barbarum Polysaccharide in Patients with Type 2 Diabetes.A 16-week study to compare the effect of vildagliptin versus gliclazide on postprandial lipoprotein concentrations and oxidative stress in patients with type 2 diabetes inadequately controlled with metformin monotherapy.Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism.Increased Plasma Dipeptidyl Peptidase-4 Activities in Patients with Coronary Artery Disease.Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study.Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients.The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes.Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes MellitusDipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial.Cardiovascular biology of the incretin system.Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report.Comparison between sitagliptin and nateglinide on postprandial lipid levels: The STANDARD study.Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats.Improved plasma FFA/insulin homeostasis is independently associated with improved glucose tolerance after a 1-year lifestyle intervention in viscerally obese men.Postprandial Hyperlipidemia and Remnant Lipoproteins.A review of gliptins in 2011.Potential cardiovascular effects of incretin-based therapies.Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.Cardiovascular effects of gliptins.Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs.
P2860
Q24628948-9D2135DB-11AE-41AF-9839-7940BA808D03Q26740253-70C8BBD5-1D14-479E-A351-1C80FFBD80A7Q26824004-4778C726-19D5-4823-858F-6E53AC54E36BQ26827183-C2FF955D-D106-483A-A69A-BFFF67D178ECQ26997149-DB86C798-DFF6-4C40-84EF-53BF14749303Q27011819-77C4B8BD-3E43-43D9-8724-47FA8A270E05Q28547367-ED2C5726-0150-4F22-A353-906EE2A1B624Q33603384-C5A41FE0-4DE8-481B-BF3C-49C3569B22E8Q33633664-663DB66C-2613-4DFB-9BBF-AD6FE41EA72DQ33789371-90759C56-06C2-4199-9915-FF1BC925C1F9Q33805518-32DF5D72-D7C7-434B-BB50-69A1A46EA930Q34016283-F47BD30D-076C-40EF-AE5A-80856FF4CE66Q34062829-7DC47B97-FB42-492E-92ED-392A38AE9531Q34064982-49DB963B-827E-4A5C-B8D7-01AB1957BAA7Q34171759-FAFECB10-F1D7-4FB8-8DD8-EBFFA6D1F0E7Q34585325-44ABB138-289F-4EB3-AF6D-858C16A58966Q34994502-EF1DB4F3-FF13-4019-ABBD-6C52EA061DA4Q35094237-1B6EAE08-0F43-42F4-8E6B-F9004435E497Q35624667-116FCA88-5FAC-445B-B79A-BF7528E563E3Q35763816-39F45CB9-14B4-482E-AD1D-47FBEDAA190AQ35844788-1B71E9F9-A2BA-42B2-9815-9D55C3FDDDF2Q35928257-F7EA97B1-F2CE-468C-BD0E-5B0455F9D563Q36139664-DCA90B6A-BB96-4E65-89E1-D82095D65190Q36209136-4CA37CA6-4E27-4D37-8D2E-ED41B2EF9704Q36254518-66B93941-5920-4490-B846-A97E98CCB47FQ36381927-8DBCDBE8-0B4B-49CF-BC62-64839E3AC1C5Q36424020-CE9DDA52-B954-448D-BCFD-42060B29D2D6Q36466692-0C3E17C0-5FA1-48D6-9E05-B9FDBF5AA3EFQ36484283-7A9DB6E0-2926-4680-9F64-3ED5BD1113A8Q36568187-60D1F715-144B-4223-A660-CF21CEF54C43Q36682246-3110A010-7BA9-4249-8393-577627568CADQ36965895-A8B59A18-4D49-4620-9A34-E1C26BC10877Q37193579-18BE027D-6285-4140-991E-3A5F096AFAE4Q37639159-5DF60C24-C66B-441F-9938-95FC5E665DAEQ37965612-565CE91D-AFE6-40FE-AB67-D172ACF3AFA8Q37990619-205C7209-CE4C-4FBD-B40F-643E1869E7DCQ38010243-1D85D62C-8D3A-47A1-A05B-D6D929E91444Q38065321-DBAED065-9440-41B8-B2E0-FE44DE18D391Q38072259-688B20EF-E0B6-4F12-ACC5-B22CAAC61874Q38107546-FD4A5025-37A7-4866-A0F6-233A5F55A815
P2860
Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Effect of sitagliptin therapy ...... patients with type 2 diabetes.
@en
Effect of sitagliptin therapy ...... patients with type 2 diabetes.
@nl
type
label
Effect of sitagliptin therapy ...... patients with type 2 diabetes.
@en
Effect of sitagliptin therapy ...... patients with type 2 diabetes.
@nl
prefLabel
Effect of sitagliptin therapy ...... patients with type 2 diabetes.
@en
Effect of sitagliptin therapy ...... patients with type 2 diabetes.
@nl
P2860
P50
P1476
Effect of sitagliptin therapy ...... patients with type 2 diabetes
@en
P2093
A J Tremblay
S J Weisnagel
P2860
P304
P356
10.1111/J.1463-1326.2011.01362.X
P577
2011-04-01T00:00:00Z